Swedish Orphan Biovitrum
| Type |
Public company (OMX: SOBI) |
|---|---|
| Industry | Pharmaceutical |
| Headquarters | Stockholm, Sweden |
| Products | medications for hematology, rheumatology, oncology and endocrinology. |
| Website | sobi.com |
Swedish Orphan Biovitrum AB (publ) (Sobi) is an international specialty healthcare company dedicated to rare diseases, based in Stockholm, Sweden.
History
Biovitrum was created in 2001 as a spinoff from Pharmacia Corp. in the wake of the merger between the parent company Pharmacia and Upjohn and Monsanto Company in 1999. Since its creation, the company has gone through multiple transitions from a research intensive and diversified company to the current entity, focused on niche pharmaceuticals and specialist medical care. Its plasma product division was sold in 2002 to Octapharma. Biovitrum retained its recombinant factor VIII product, Refacto, which has been a major source of revenue during the company's early consolidation phase. In 2005, Biovitrum acquired the Swedish biotech company Arexis and the British company Cambridge Biotechnology Ltd, strengthening its portfolio in bio-pharmaceuticals and clinical projects. The company's in-house research effort has been reduced over the years and it is now more reliant on in-licensing for its project portfolio management.
In January 2010 Biovitrum acquired Swedish Orphan International Holding AB and in June 2010 the company was renamed Swedish Orphan Biovitrum AB (publ).[1]
Company
Today Sobi is an international specialty healthcare company dedicated to rare diseases. The company's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. Sobi also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm.